Cargando…
Identification of enzymes involved in oxidation of phenylbutyrate
In recent years the short-chain fatty acid, 4-phenylbutyrate (PB), has emerged as a promising drug for various clinical conditions. In fact, PB has been Food and Drug Administration-approved for urea cycle disorders since 1996. PB is more potent and less toxic than its metabolite, phenylacetate (PA)...
Autores principales: | Palir, Neža, Ruiter, Jos P. N., Wanders, Ronald J. A., Houtkooper, Riekelt H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Biochemistry and Molecular Biology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408614/ https://www.ncbi.nlm.nih.gov/pubmed/28283530 http://dx.doi.org/10.1194/jlr.M075317 |
Ejemplares similares
-
Mitochondrial Fatty Acid Oxidation Disorders: Laboratory Diagnosis, Pathogenesis, and the Complicated Route to Treatment
por: Wanders, Ronald J.A., et al.
Publicado: (2020) -
NAD(+) homeostasis in human health and disease
por: Zapata‐Pérez, Rubén, et al.
Publicado: (2021) -
Identification of longevity compounds with minimized probabilities of side effects
por: Janssens, Georges E., et al.
Publicado: (2020) -
Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle
por: Knottnerus, Suzan J. G., et al.
Publicado: (2018) -
The enzymology of mitochondrial fatty acid beta-oxidation and its application to follow-up analysis of positive neonatal screening results
por: Wanders, Ronald J. A., et al.
Publicado: (2010)